Influenza and RSV incidence during COVID-19 pandemic—an observational study from in-hospital point-of-care testing
Medical Microbiology and Immunology · 2021-12 · 210 (5-6) · 277-282
DOI: 10.1007/s00430-021-00720-7 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Medical Microbiology and Immunology, online erschienen am 04.10.2021. Verfasst von Paul Stamm und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Cardiology I, University Medical Center Mainz, Geb. 605, Langenbeckstr. 1, 55131, Mainz, Germany. paul.stamm@unimedizin-mai…. Die Arbeit wurde bisher 82-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsmedizin der Johannes Gutenberg-Universität Mainz.
Abstract (Originalsprache)
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has forced the implementation of unprecedented public health measures strategies which might also have a significant impact on the spreading of other viral pathogens such as influenza and Respiratory Syncytial Virus (RSV) . The present study compares the incidences of the most relevant respiratory viruses before and during the SARS-CoV-2 pandemic in emergency room patients. We analyzed the results of in total 14,946 polymerase chain reaction point-of-care tests (POCT-PCR) for Influenza A, Influenza B, RSV and SARS-CoV-2 in an adult and a pediatric emergency room between December 1, 2018 and March 31, 2021. Despite a fivefold increase in the number of tests performed, the positivity rate for Influenza A dropped from 19.32% (165 positives of 854 tests in 2018/19), 14.57% (149 positives of 1023 in 2019–20) to 0% (0 positives of 4915 tests) in 2020/21. In analogy, the positivity rate for Influenza B and RSV dropped from 0.35 to 1.47%, respectively, 10.65–21.08% to 0% for both in 2020/21. The positivity rate for SARS-CoV2 reached 9.74% (110 of 1129 tests performed) during the so-called second wave in December 2020. Compared to the two previous years, seasonal influenza and RSV incidence was eliminated during the COVID-19 pandemic. Corona-related measures and human behavior patterns could lead to a significant decline or even complete suppression of other respiratory viruses such as influenza and RSV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Cardiology I, University Medical Center Mainz, Geb. 605, Langenbeckstr. 1, 55131, Mainz, Germany. paul.stamm@unimedizin-mainz.de.
- German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Mainz, Germany. paul.stamm@unimedizin-mainz.de.
- Department of Cardiology, Cardiology I, University Medical Center Mainz, Geb. 605, Langenbeckstr. 1, 55131, Mainz, Germany.
- Institute for Virology, University Medical Center Mainz, Mainz, Germany.
- German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Mainz, Germany.
Förderung
- Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Zitieren
APA
Stamm, P., Sagoschen, I., Weise, K., Plachter, B., Münzel, T., Gori, T., & Vosseler, M. (2021). Influenza and RSV incidence during COVID-19 pandemic—an observational study from in-hospital point-of-care testing. Medical Microbiology and Immunology, 210(5-6), 277-282. https://doi.org/10.1007/s00430-021-00720-7
Vancouver
Stamm P, Sagoschen I, Weise K, Plachter B, Münzel T, Gori T, et al. Influenza and RSV incidence during COVID-19 pandemic—an observational study from in-hospital point-of-care testing. Medical Microbiology and Immunology. 2021;210(5-6):277-282. doi:10.1007/s00430-021-00720-7
BibTeX
@article{Stamm2021,
author = {Stamm, Paul and Sagoschen, Ingo and Weise, Kerstin and Plachter, Bodo and Münzel, Thomas and Gori, Tommaso and Vosseler, Markus},
title = {Influenza and RSV incidence during COVID-19 pandemic—an observational study from in-hospital point-of-care testing},
journal = {Medical Microbiology and Immunology},
year = {2021},
volume = {210},
number = {5-6},
pages = {277--282},
doi = {10.1007/s00430-021-00720-7}
}
EUVIMED